Faeth Therapeutics(DE:4070)
€10.70-0.70 (-41.85%)
DE:4070
Faeth Therapeutics stock forecast
€10.70
At close:-0.70 (-41.85%)
Faeth Therapeutics (4070) Stock Forecast & Price Target
1 Followers
4070 Analyst Ratings
Strong Buy
10Buy0Hold0Sell
Based on 10 analysts giving stock ratings to Faeth Therapeutics in the past 3 months
4070 Stock 12 Month Forecast
Average Price Target
€51.73▲(383.47% Upside)Based on 10 Wall Street analysts offering 12 month price targets for Faeth Therapeutics in the last 3 months. The average price target is EUR 51.73 with a high forecast of EUR 61.78 and a low forecast of EUR 35.81. The average price target represents a 383.47% change from the last price of EUR 10.70.
Past 12 Months12 Month ForecastJan2026Oct2026
High€61.78
Average€51.73
Low€35.81
Highest Price TargetHighest€61.78Average Price Target€51.73Lowest Price TargetLowest€35.81
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Article | |||||||
|---|---|---|---|---|---|---|---|---|
| Patrick Trucchio | H.C. Wainwright | €53.72 | buy | 402.07%Upside | Reiterated | 11/11/26 | ||
| Geoff Meacham | Citi | €49.24→€53.72 | buy | 402.07%Upside | Assigned | 11/10/26 | ||
| Jeet Mukherjee | BTIG | €49.24 | buy | 360.23%Upside | Reiterated | 11/09/26 | ||
| Dev Prasad | Lucid Capital | €52.83 | buy | 393.70%Upside | Reiterated | 11/09/26 | ||
| Bradley Canino | Guggenheim | €61.78 | buy | 477.38%Upside | Reiterated | 11/09/26 | ||
| Boris Peaker | JonesTrading | €49.24 | buy | 360.23%Upside | Reiterated | 11/03/26 | ||
| Oliver McCammon | LifeSci Capital | €35.81 | buy | 234.71%Upside | Initiated | 10/15/26 | ||
| Alethia Young | William Blair | €59.09 | buy | 452.27%Upside | Initiated | 10/15/26 | ||
| Tara Bancroft | TD Cowen | ― | buy | ― | Initiated | 09/09/26 | ||
| Gil Blum | Needham | €50.14 | buy | 368.59%Upside | Initiated | 08/21/26 | ||
| Jay Olson | Oppenheimer | €53.72 | buy | 402.07%Upside | Reiterated | 08/05/26 | ||
| Sean McCutcheon | Raymond James | €50.14 | buy | 368.59%Upside | Initiated | 07/31/26 | ||
| Silvan Turkcan | Citizens JMP | €45.66 | buy | 326.76%Upside | Initiated | 07/20/26 | ||
| Jack Allen | Robert W. Baird | €51.03 | buy | 376.96%Upside | Initiated | 06/26/26 | ||
| Li Watsek | Cantor Fitzgerald | ― | buy | ― | Reiterated | 06/03/26 |
| Rating | Article | ||||
|---|---|---|---|---|---|
| Patrick TrucchioH.C. Wainwright | BuyReiterated€53.72 | 11/11/26 | 402.07%Upside | ||
| Geoff MeachamCiti | BuyAssigned€49.24→€53.72 | 11/10/26 | 402.07%Upside | ||
| Jeet MukherjeeBTIG | BuyReiterated€49.24 | 11/09/26 | 360.23%Upside | ||
| Dev PrasadLucid Capital | BuyReiterated€52.83 | 11/09/26 | 393.70%Upside | ||
| Bradley CaninoGuggenheim | BuyReiterated€61.78 | 11/09/26 | 477.38%Upside | ||
| Boris PeakerJonesTrading | BuyReiterated€49.24 | 11/03/26 | 360.23%Upside | ||
| Oliver McCammonLifeSci Capital | BuyInitiated€35.81 | 10/15/26 | 234.71%Upside | ||
| Alethia YoungWilliam Blair | BuyInitiated€59.09 | 10/15/26 | 452.27%Upside | ||
| Tara BancroftTD Cowen | BuyInitiated | 09/09/26 | ― | ||
| Gil BlumNeedham | BuyInitiated€50.14 | 08/21/26 | 368.59%Upside | ||
| Jay OlsonOppenheimer | BuyReiterated€53.72 | 08/05/26 | 402.07%Upside | ||
| Sean McCutcheonRaymond James | BuyInitiated€50.14 | 07/31/26 | 368.59%Upside | ||
| Silvan TurkcanCitizens JMP | BuyInitiated€45.66 | 07/20/26 | 326.76%Upside | ||
| Jack AllenRobert W. Baird | BuyInitiated€51.03 | 06/26/26 | 376.96%Upside | ||
| Li WatsekCantor Fitzgerald | BuyReiterated | 06/03/26 | ― |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering Faeth Therapeutics
3 Months
Success Rate3/4 ratings generated profit
75%
Average Return
+76.55%
Copying Geoff Meacham's trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +76.55% per trade.
1 Year
Success Rate3/4 ratings generated profit
75%
Average Return
+30.08%
Copying Geoff Meacham's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +30.08% per trade.
2 Years
Success Rate3/4 ratings generated profit
75%
Average Return
+30.08%
Copying Geoff Meacham's trades and holding each position for 2 Years would result in 75.00% of your transactions generating a profit, with an average return of +30.08% per trade.
4070 Analyst Recommendation Trends
| Rating | Jul 26 | Aug 26 | Sep 26 | Oct 26 | Nov 26 |
|---|---|---|---|---|---|
| Strong Buy | 13 | 17 | 15 | 16 | 19 |
| Buy | 2 | 1 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 15 | 18 | 17 | 18 | 21 |
In the current month, 4070 has received 21 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 4070 average Analyst price target in the past 3 months is 51.73.
4070 Financial Forecast
High€-0.61
Consensus€-0.76
Low€-1.23
4070 Earnings Forecast
Next quarter’s earnings estimate for 4070 is -EUR 0.76 with a range of -EUR 1.23 to -EUR 0.61. The previous quarter’s EPS was -EUR 0.71. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
High€0.00
Consensus€0.00
Low€0.00
4070 Sales Forecast
Next quarter’s sales forecast for 4070 is EUR 0 with a range of EUR 0 to EUR 0. The previous quarter’s sales results were EUR 0. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
4070 Stock Forecast FAQ
What is DE:4070’s average 12-month price target, according to analysts?
Based on analyst ratings, Faeth Therapeutics’s 12-month average price target is €51.73.
What is DE:4070’s upside potential, based on the analysts’ average price target?
Faeth Therapeutics has 383.47% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Faeth Therapeutics a Buy, Sell or Hold?
Faeth Therapeutics has a consensus rating of Strong Buy, which is based on 10 buy ratings, 0 hold ratings and 0 sell ratings.
What is Faeth Therapeutics’s share price target?
The average share price target for Faeth Therapeutics is €51.73. This is based on 10 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is €61.78, and the lowest forecast is €35.81. The average share price target represents a 383.47% increase from the current price of €10.7.
What do analysts say about Faeth Therapeutics?
Faeth Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Street analysts.
How can I buy shares of Faeth Therapeutics?
To buy shares of DE:4070, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
